Reports of Miraculous Cures Using Orthomolecular Medicine

Introduction
There have been reports favoring the use of omega-3 fatty acids for a number of diseases including heart disease, depression, glaucoma, etc. This point of view has been favored by Dr. Andrew Weil (1).
Glaucoma
Ref. 2 is about glaucoma. Although Ref. 2 is a review, it is a very comprehensive one. This gem led me to Ref. 3, which is very positive. Ref. 3 is from the

Department of Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia.

The Australian study was done on rats.
"Increasing dietary omega-3 reduces IOP with age because of increased outflow facility, likely resulting from an increase in docosanoids. This indicates that dietary manipulation may provide a modifiable factor for IOP regulation." Nguyen et al (3)
"The Western diet is relatively deficient in ω-3 PUFAs because of a higher intake of ω-6-rich oils (e.g., many common vegetable oils), margarines, and meats, ⁵ in contrast to the traditional Japanese diet, which is high in ω-3-rich fish. ⁶ Western populations have a higher prevalence of many systemic diseases, such as cardiovascular disease, than the traditional Japanese population, and an association has been suggested between disease prevalence and dietary intake. ⁷ SanGiovanni and Chew ⁴ recently reviewed evidence suggesting that ω-3 deprivation may predispose to ocular disease later in life." Nguyen et al (3)
The references listed in this quote are the references from the Australian article. However, I have listed their Ref. 4 as my Ref. 4 because this reference appeared to be important.
Body Mass Index
Ref. 3 reviewed research on BMI and glaucoma. BMI was found to be correlated with intraocular pressure (IOP). Your BMI is a measure of how fat you are. A high BMI is a risk factor for diabetes and other diseases.
"Many studies document a positive association between BMI and IOP." Pasquale et al (2)
Ref. 5 found a positive correlation as did Ref. 6.

"Body mass index, a measure of obesity, was correlated positively with IOP." Klein et al (6)

Thus obesity appears to be a lifestyle factor that worsens glaucoma.

Vitamin C

There is also a point of view that favors the use of vitamin C to treat glaucoma. This view was favored by the late Dr. Irwin Stone in his 1972 book called "The Healing Factor". Dr. Andrew Saul of Canada favors this approach.

Hypertension

The Beaver Dam Eye Study also found an association of IOP with blood pressure. Thus it is very important to avoid hypertension.

Cancer

Unfortunately Linus Pauling and Irwin Stone are both deceased. Both favored the use of megavitamin therapy with vitamin C for cancer. However, Dr. Cameron may still be alive. Refs. 7-66 are about cancer.

Introduction

Because hypertension and heart failure were not dealt with adequatel here, I may write a new article about these very important topics. Hypertension is a disease of the kidneys causing high blood pressure. This happens more often in older people. Sodium must be restricted in the diet and potassium is encouraged. Hypertension is a risk factor for both heart failure and stroke.

References

1. www.drweil.com .

2. Lifestyle, nutrition, and glaucoma. Pasquale LR, Kang JH. J Glaucoma . 2009 Aug;18(6):423-8. Review.

3. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):756-62. Dietary omega 3 fatty acids decrease intraocular pressure with age by increasing aqueous outflow. Nguyen CT , Bui BV , Sinclair AJ , Vingrys AJ .

4. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res . 2005 ; 24 : 87 -138.

5. Jpn J Ophthalmol. 2003 Mar-Apr;47(2):191-8. Association of life-style with intraocular pressure in middle-aged and older Japanese residents. Yoshida M , Ishikawa M , Kokaze A , Sekine Y , Matsunaga N , Uchida Y , Takashima Y .

6. Invest Ophthalmol Vis Sci. 1992 Jun;33(7):2224-8. Intraocular pressure in an American community. The Beaver Dam Eye Study. Klein BE , Klein R , Linton KL .

7. Cameron, E. and Pauling, L. (1976) Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences USA. 73:3685-3689.

8. Cameron, E. and Pauling, L. (1978) Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences USA. 75:4538-4542

9. Morishige, F. and Murata, A. (1979) Prolongation of survival times in terminal human cancer by administration of supplemental ascorbate. Journal of the International Academy of Preventive Medicine. 5:47-52

10. Murata, A., Morishige, F. and Yamaguchi, H. (1982) Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. International Journal of Vitamin and Nutrition Research Suppl., 23, 1982, p. 103-113. Also in Hanck, A., ed. (1982) Vitamin C: New Clinical Applications. Bern: Huber, 103-113.

11. Rather D. CBS Network News; January 20, 1985.

12. Cameron, E. and Pauling, L. (1974) The orthomolecular treatment of cancer. 1. The role of ascorbate in host resistance. Chemical-Biological Interactions. 9:273-283.

13. Cameron E, Pauling L, Leibovitz B. (1979) Ascorbic acid and cancer: a review. Cancer Research 39, 663-681.

14. Cameron E, Pauling L. Cancer and Vitamin C. Linus Pauling Institute of Science and Medicine, Menlo Park, Ca. (1979); (Weidenfeld and Nicholson, London 1980; Kyoritsu Shuppan KK, Tokyo 1981; Warner Books, New York 1981; Services Complet d'Editions, Quebec and Paris 1982).

15. Yonemoto RH, Chretien PB, Fehnoer TF. Enhanced lymphocyte blastogenesis by oral ascorbic acid. Proc Am Assn Cancer Res 1976; 17:288.

16. Anderson R. Ascorbic acid and immune functions: mechanisms of immunostimulation. In, Counsell JN, Hornig DH (eds), Vitamin C. London, Applied Science Publishers 1981: 249-272.

17. Panush RS, Delafluente JC, Katz P, Johnson J. Modulation of certain immunologic responses by vitamin C. Ill. Potentiation of in vitro and in vivo lymphocyte responses. Int J Vitamin Nutr Res 1982; 23:35-37.

18. Siegel BV , Morton JI. Vitamin C and the immune response. Experimentia 1977; 33:393-395.

19. Siegel BV , Leibovitz B. The multifactorial role of vitamin C in health and disease. Int J Vitamin Nutr Res 1982; 23:9-22.

20. Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole. Oncology 1969; 23:33-43.

21. Yamafuji K, Nakamura Y, Omura H, Soeda T, Gyotoku K. Anti-tumor potency of ascorbic, dehydroascorbic, or 2,3-diketogulonic acid and their action on deoxyribonucleic acid. Z Krebsforsch 1971; 76:1-7.

22. Yagashita K, Takahashi N, Yamamoto H, Jinnouchi H, Hiyoshi S, Miyakawa T. Effects of tetraacetyl-bis-dehydroascorbic acid, a derivative of ascorbic acid, on Ehrlich cells and HeLa cells (human carcinoma cells). J Nut Sci Vitaminol 1976; 22:419-427.

23. Cameron, E. and Campbell, A. (1974) The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic supplements in advanced human cancer. Chemical-Biological Interactions 9:285-315.

24. Cameron E, Campbell A, Jack T. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 1975; 11:387-393.

25. Creagan FT, Moertel CG, O'FalIon JR et al. Failure of high-dose vitamin C (ascorbic acid) to benefit patients with advanced cancer: a controlled trial. N Eng J Med 1979; 301:687-690.

26. Moertel CG, Fleming TR, Creagan FT et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. N Eng J Med 1985; 312:137-141.

27. Pauling, L (1980) Vitamin C therapy of advanced cancer (letter). New Eng. J. Med. 302, 694-695 (1980).

28. Cameron E. Vitamin C for cancer (letter). N Eng J Med 1980; 302:299.

29. Koch CJ, Biaglow JE. Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. J Cell Physiol 1978; 94:299-306.

30. Veltri RW, Maxim PE, Baseler MW, Cameransi BG, Kinger MR. L-ascorbic acid (vitamin C) augmentation of anticancer activity of methoxy-substituted benzoquinones, adriamycin and a dihydroxylated amino substituted quinone (DHAQ). (Submitted 1987 to Cancer Research)

31. Meredith P. (Linus Pauling Institute of Science and Medicine) Unpublished observations, 1983.

32. Cameron E, Moffat L, Campbell A, Marcuson R. Supplemental ascorbate in incurable cancer: an epidemiological study. (Submitted 1984 to N Eng J Med)

33. Campbell A, Jack T. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J 1979; 24:151-153.

34. Burke M. My successful fight against cancer: Burke, The Malt House, Warwick, 1982.

35. Hughes RE. Recommended daily amounts and biochemical roles - the vitamin C, carnitine, fatigue relationship. In Counsell JN, Hornig DH (eds), Vitamin C. Applied Science publishers, London 1982: 75-86.

36. Cameron E. Vitamin C and cancer cachexia: the carnitine connection. In Huemer RP (ed), The Roots of MolecuIar Medicine: A Tribute to Linus Pauling. W.H. Freeman and Co., New York 1986: 133-139.

37. Cameron E. Vitamin C, carnitine and cancer, or "My God. I Feel So Much Better, Doctor!" In Bland JS (ed), 1986: A Year in Nutritional Medicine. Keats Publishing Inc.) New Canaan) Connecticut 1986: 115-123.

38. Cameron, E. and Baird, G. (1973) Ascorbic acid and dependence on opiates in patients with advanced and disseminated cancer. Journal of International Research Communications. 1:38, August.

39. Basu TK, Raven RW, Dickerson JWT, Williams DC. Leucocyte ascorbic acid and urinary hydroxyproline levels in patients bearing breast cancer with skeletal metastases. Eur J Cancer, 1974; 10:507-511.

40. Lamden MP, Chrystowski GA. Urinary oxalate excretion by man following ascorbic acid ingestion. Proc Soc Exp Biol Med 1954; 85:190-198.

41. Fituri N, Allawi N, Bentley M, Costello J. Urinary and plasma oxalate during ingestion of pure ascorbic acid: a reevaluation. Eur UroI 1983; 9:312-315.

42. Tsao CS. Ascorbic acid and urinary oxalate (letter). Ann Int Med 1984; 101:405.

43. Tsao CS, Salimi SL. Effect of large intake of ascorbic acid on urinary and plasma oxalic acid levels. Int J Vitamin Nutr Res 1984; 54:245-249.

44. Hoffer A. Vitamin C and infertility (letter). Lancet 1973; ii:1146.

45. Cameron E. Hyaluronidase and Cancer. Pergamon Press, Oxford, London and New York. 1966.

46. Cameron F, Rotman D. Ascorbic acid, cell proliferation and cancer (letter). Lancet 1972; i :542.

47. Cameron, E. and Pauling, L. (1973) Ascorbic acid and the glycosaminoglycans: An orthomolecular approach to cancer and other diseases. Oncology (Basel) 27: 181-192.

48. Cameron E. Vitamin C (letter). Brit J Hosp Med 1975; 13:511.

49. Cameron E. Biological function of ascorbic acid and the pathogenesis of scurvy. Medical Hypothesis, 1976; 2:154-163.

50. Cameron E, Pauling L. Experimental studies designed to evaluate the management of patients with incurable cancer. Proc Natl Acad Sci USA 1978; 75:6252.

51. Cameron E, Pauling L. (1979) Ascorbate and cancer. Proc. Am. Phil. Soc. 123:117-123.

52. Cameron E, Pauling L (1978) Ascorbic acid as a therapeutic agent in cancer. J. Intern. Acad. Prev. Med. 5 (1), 8-29

53. Cameron F, Pauling L. (1981) Survival times of terminal lung cancer patients treated with ascorbate. J. Intern. Acad. Prev. Med. 6: 21-27.

54. Cameron, Ewan (1982) Vitamin C and cancer: an overview. International Journal of Vitamin and Nutrition Research Suppl. 23.

55. Cameron F. Vitamin C and cancer: an overview. In Hanck A (ed). Vitamin C. New Clinical Applications. Huber; Bern, Stuttgart and Vienna 1982, p115-127.

56. Moffat L, Cameron E, Campbell A. High dose ascorbate therapy and cancer. In McBrien DCH, Slater TF (eds), Protective Agents in Cancer. Academic Press, London and New York 1983:243-256.

57. Cameron E and Pauling L (1978) Ascorbic acid as a therapeutic agent in cancer. J. Intern. Acad. Prev. Med. 5 (1), 8-29.

58. Cameron E and Pauling L (1980) On cancer and vitamin C. Executive Health 16 (4), 1-8. Jan.

59. Cameron E and Pauling L (1981) Survival times of terminal lung cancer patients treated with ascorbate. J. Intern. Acad. Prev. Med. 6) 21-27.

60. Cameron E and Pauling L (1982) Megadoses of vitamin C as an adjunct in the treatment of cancer. Your Patient and Cancer 2, 39-46. May.

61. Pauling L and Cameron E (1983) Vitamin C and cancer. Australasian Health & Healing 2 (3), 9-10 (April-June).

62. Cameron, Ewan (Undated, c.1986-88) Protocol for the use of intravenous vitamin C in the treatment of cancer. Linus Pauling Institute of Science and Medicine, Palo Alto, California. 8 pp.
63. Cameron E and Pauling L (1987) Vitamin C and AIDS. Washington Post Health, p. 4. Feb. 3.

64. Cameron, E. (1991) Protocol for the use of vitamin C in the treatment of cancer. Medical Hypotheses. 36:190-194.

65. Cameron, E. and Campbell, A. (1991) Innovation vs. quality control: an "unpublishable" clinical trial of supplemental ascorbate in incurable cancer. Medical Hypotheses, 36(3), p 185-189, November.

66. Cameron, E. and Pauling, L. (1993) Cancer and Vitamin C, revised edition. Philadelphia: Camino Books.